EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells

Jiantao Wang, Nasim Pouryaghoub, Robert Strauss iD, Jiri Bartek, Si Min Zhang, Sean G Rudd iD

Fundamental & Clinical Pharmacology · 2025-10 · 39 (5)

DOI: 10.1111/fcp.70044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 10.08.2025. Verfasst von Jiantao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Lung Neoplasms, Ovarian Neoplasms, Drug Resistance, Neoplasm, Cisplatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Barncancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cisplatin and its derivatives remain a cornerstone in the treatment of solid malignancies. Resistance is a major factor limiting their clinical utility.

Objectives

In the present study, we set out to interrogate therapeutic approaches to target cisplatin‐resistant cancer cells. We focused on therapies exploiting metabolic pathways that are altered in drug‐resistant cells. We sought to find an existing therapy that has monotherapy efficacy against cisplatin‐resistant cancer cells that can also re‐sensitize to cisplatin.

Methods

We used lung and ovarian cancer cell lines with acquired resistance to cisplatin together with drug sensitivity assays, conducted both with monotherapies and cisplatin combinations.

Results

We show that cancer cell lines with acquired resistance to cisplatin have altered levels of enzymes involved in glutamine metabolism, which can result in differential sensitivity to targeted agents. We show that expression of one of these enzymes—the glutamate‐cystine antiporter SLC7A11, up‐regulated 6‐fold in a cisplatin‐resistant lung cancer cell line—has potential prognostic significance in lung cancer but not ovarian cancer. After identifying a common dependency of cisplatin‐resistant cancer cells upon extracellular glutamine, we then evaluate the utility of the long‐standing anti‐leukemic therapy asparaginase (ASNase)—which possesses both asparaginase and glutaminase activity—as a potential approach. We show ASNase preferentially inhibits the proliferation of cisplatin‐resistant cancer cells and can potentially re‐sensitize these cells to cisplatin.

Conclusions

Our results underpin the prevalence of altered metabolism in cisplatin‐resistant cells and highlight the potential utility of re‐purposing ASNase to target these cells, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsOvarian NeoplasmsDrug Resistance, NeoplasmCisplatinAsparaginaseAntineoplastic AgentsHumansFemaleCell Line, TumorGlutamineAmino Acid Transport System y+Cell ProliferationDrug Repositioning

Stichwörter der Autor:innen

SLC7A11asparaginase (ASNase)chemoresistancecisplatinglutaminemetabolic rewiring

Substanzen

CisplatinGlutamineSLC7A11 protein, humanAmino Acid Transport System y+AsparaginaseAntineoplastic Agents

Autor:innen und Institutionen

  • Science for Life Laboratory (SciLifeLab), Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark.
  • Science for Life Laboratory (SciLifeLab), Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.

ORCID-Profile: Robert Strauss, Sean G Rudd

Förderung

  • Vetenskapsrådet
  • Cancerfonden
  • Barncancerfonden
  • Åke Wiberg Stiftelse
  • Danish Cancer Society
  • Fabrikant Chas. Otzen's Fond
  • Købmand Niels Erik Munk Pedersen Fonden
  • West China Hospital, Sichuan University

Zitieren

APA

Wang, J., Pouryaghoub, N., Strauss, R., Bartek, J., Zhang, S. M., & Rudd, S. G. (2025). Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells. Fundamental & Clinical Pharmacology, 39(5). https://doi.org/10.1111/fcp.70044

Vancouver

Wang J, Pouryaghoub N, Strauss R, Bartek J, Zhang SM, Rudd SG. Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells. Fundamental & Clinical Pharmacology. 2025;39(5). doi:10.1111/fcp.70044

BibTeX
@article{Wang2025,
  author = {Wang, Jiantao and Pouryaghoub, Nasim and Strauss, Robert and Bartek, Jiri and Zhang, Si Min and Rudd, Sean G},
  title = {Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  volume = {39},
  number = {5},
  doi = {10.1111/fcp.70044}
}
Kostenlos starten →